Wells Fargo & Company Begins Coverage on Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wells Fargo initiated coverage of Supernus Pharmaceuticals with an “overweight” rating and a $54 price target, implying about 90% upside from the stock’s then-current price.
  • Analysts’ overall view was “Moderate Buy,” with a consensus price target of $59.17; recommendations ranged from strong buy to hold.
  • Supernus missed quarterly expectations, reporting EPS of $0.35 versus $0.49 expected and revenue of $208.6 million versus $217.56 million expected, despite year-over-year revenue growth of 18%.
  • Five stocks we like better than Supernus Pharmaceuticals.

Analysts at Wells Fargo & Company assumed coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) in a report issued on Friday, Briefing.com reports. The firm set an "overweight" rating and a $54.00 price target on the specialty pharmaceutical company's stock. Wells Fargo & Company's target price would suggest a potential upside of 90.48% from the stock's current price.

A number of other equities research analysts have also commented on SUPN. Jefferies Financial Group initiated coverage on Supernus Pharmaceuticals in a research report on Wednesday, November 4th. They set a "strong-buy" rating on the stock. Cantor Fitzgerald lifted their price objective on Supernus Pharmaceuticals from $67.00 to $87.00 and gave the company an "overweight" rating in a research report on Wednesday, November 4th. Bank of America assumed coverage on Supernus Pharmaceuticals in a research note on Monday, November 9th. They issued a "buy" rating and a $47.00 price objective on the stock. Piper Sandler initiated coverage on Supernus Pharmaceuticals in a report on Wednesday, November 4th. They set an "overweight" rating and a $47.00 target price on the stock. Finally, Zacks Research lowered Supernus Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Supernus Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $59.17.

Read Our Latest Research Report on SUPN

Supernus Pharmaceuticals Stock Down 2.1%

Shares of Supernus Pharmaceuticals stock opened at $28.35 on Friday. Supernus Pharmaceuticals has a 12-month low of $25.92 and a 12-month high of $42.81. The stock has a market capitalization of $3.35 billion, a P/E ratio of 7.92, a price-to-earnings-growth ratio of 0.58 and a beta of 0.84. The company has a 50-day simple moving average of $38.43 and a 200 day simple moving average of $45.91.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.14). The firm had revenue of $208.60 million for the quarter, compared to the consensus estimate of $217.56 million. Supernus Pharmaceuticals had a negative return on equity of 418.04% and a net margin of 32.75%. Supernus Pharmaceuticals's quarterly revenue was up 18.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.80) earnings per share. On average, equities analysts anticipate that Supernus Pharmaceuticals will post 3.80 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SUPN. Summit Global Investments raised its stake in Supernus Pharmaceuticals by 6.1% in the 1st quarter. Summit Global Investments now owns 4,436 shares of the specialty pharmaceutical company's stock valued at $229,000 after acquiring an additional 256 shares during the period. PNC Financial Services Group Inc. boosted its position in Supernus Pharmaceuticals by 2.3% during the first quarter. PNC Financial Services Group Inc. now owns 14,548 shares of the specialty pharmaceutical company's stock worth $752,000 after purchasing an additional 321 shares during the period. Corient Private Wealth LP boosted its position in Supernus Pharmaceuticals by 6.6% during the second quarter. Corient Private Wealth LP now owns 5,163 shares of the specialty pharmaceutical company's stock worth $240,000 after purchasing an additional 321 shares during the period. Juncture Wealth Strategies LLC increased its holdings in shares of Supernus Pharmaceuticals by 5.8% in the third quarter. Juncture Wealth Strategies LLC now owns 6,778 shares of the specialty pharmaceutical company's stock valued at $292,000 after purchasing an additional 374 shares during the last quarter. Finally, Illinois Municipal Retirement Fund raised its position in shares of Supernus Pharmaceuticals by 1.4% in the third quarter. Illinois Municipal Retirement Fund now owns 31,359 shares of the specialty pharmaceutical company's stock valued at $1,124,000 after purchasing an additional 440 shares during the period.

Supernus Pharmaceuticals Company Profile

(Get Free Report)

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. Its work spans neurology and psychiatry, including therapies for epilepsy, attention-deficit/hyperactivity disorder (ADHD), and Parkinson's disease. The company's marketed products include Qelbree for ADHD; Oxtellar XR and Trokendi XR for epilepsy; and medicines for Parkinson's disease, including Apokyn, Xadago, and Ongentys. Its portfolio also includes Gocovri, which is used to treat certain movement complications associated with Parkinson's disease.

Read More

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Supernus Pharmaceuticals Right Now?

Before you consider Supernus Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.

While Supernus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines